Nothing Special   »   [go: up one dir, main page]

SK25099A3 - Substituted cyclic amine metalloprotease inhibitors - Google Patents

Substituted cyclic amine metalloprotease inhibitors Download PDF

Info

Publication number
SK25099A3
SK25099A3 SK250-99A SK25099A SK25099A3 SK 25099 A3 SK25099 A3 SK 25099A3 SK 25099 A SK25099 A SK 25099A SK 25099 A3 SK25099 A3 SK 25099A3
Authority
SK
Slovakia
Prior art keywords
mmol
hydroxycarboxamido
methoxyphenylsulfonyl
alkyl
etoac
Prior art date
Application number
SK250-99A
Other languages
English (en)
Slovak (sk)
Inventor
Michael G Natchus
Biswanath De
Stanislaw Pikul
Neil G Almstead
Roger G Bookland
Yetunde O Taiwo
Menyan Cheng
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of SK25099A3 publication Critical patent/SK25099A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42Nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Confectionery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
SK250-99A 1996-08-28 1997-08-22 Substituted cyclic amine metalloprotease inhibitors SK25099A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2484296P 1996-08-28 1996-08-28
PCT/US1997/014555 WO1998008815A1 (en) 1996-08-28 1997-08-22 Substituted cyclic amine metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
SK25099A3 true SK25099A3 (en) 2000-02-14

Family

ID=21822685

Family Applications (1)

Application Number Title Priority Date Filing Date
SK250-99A SK25099A3 (en) 1996-08-28 1997-08-22 Substituted cyclic amine metalloprotease inhibitors

Country Status (30)

Country Link
US (6) US6417219B1 (id)
EP (1) EP0927161B1 (id)
JP (2) JP3541043B2 (id)
KR (1) KR100323272B1 (id)
CN (1) CN1232451A (id)
AT (1) ATE226193T1 (id)
AU (1) AU741893B2 (id)
BR (1) BR9713465A (id)
CA (1) CA2263928A1 (id)
CO (1) CO4900036A1 (id)
CZ (1) CZ63199A3 (id)
DE (1) DE69716449T2 (id)
DK (1) DK0927161T3 (id)
ES (1) ES2201318T3 (id)
HK (1) HK1020962A1 (id)
HU (1) HUP0000478A3 (id)
ID (1) ID18143A (id)
IL (1) IL128666A (id)
MY (1) MY116959A (id)
NO (1) NO315371B1 (id)
NZ (1) NZ334256A (id)
PE (1) PE109098A1 (id)
PL (1) PL331802A1 (id)
PT (1) PT927161E (id)
RU (1) RU2221782C2 (id)
SK (1) SK25099A3 (id)
TR (1) TR199900431T2 (id)
TW (1) TWI232218B (id)
WO (1) WO1998008815A1 (id)
ZA (1) ZA977698B (id)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
AU725831C (en) * 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
AU741893B2 (en) * 1996-08-28 2001-12-13 Procter & Gamble Company, The Substituted cyclic amine metalloprotease inhibitors
US6872742B2 (en) * 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
CA2280151C (en) 1997-02-11 2005-12-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HUP0004595A3 (en) 1997-07-31 2001-12-28 Procter & Gamble Acyclic metalloprotease inhibitors
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
CN1195735C (zh) 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
IL139248A0 (en) * 1998-05-14 2001-11-25 Du Pont Pharm Co Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
CN1320028A (zh) * 1998-09-30 2001-10-31 宝洁公司 使用磺酰胺治疗脱发的方法
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1147085B1 (en) 1999-01-27 2005-11-16 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
KR20010102485A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 디헤테로-치환된 메탈로프로테아제 저해제
CN1349498A (zh) 1999-03-03 2002-05-15 宝洁公司 含有链烯基和炔基的金属蛋白酶抑制剂
AU3196100A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
AU6388500A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent sulfonamides
AU6499000A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent compounds
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
JP2003528072A (ja) 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー マトリックスメタロプロテアーゼおよびTNF−αの阻害剤としての環状β−アミノ酸誘導体
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
KR100372757B1 (ko) * 2000-04-07 2003-02-17 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
AU2001271544A1 (en) 2000-06-30 2002-01-14 The Procter And Gamble Company Oral compositions comprising host-response modulating agent
KR100568841B1 (ko) * 2000-07-19 2006-04-10 에프. 호프만-라 로슈 아게 엔도텔린-전환 효소의 억제제로서의 피롤리딘 유도체
AU7847901A (en) * 2000-07-19 2002-02-05 Hoffmann La Roche Pyrrolidine derivatives as metalloprotease inhibitors
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
MXPA04004010A (es) 2001-11-01 2004-07-23 Wyeth Corp Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
EP1452527B1 (en) 2001-11-13 2009-03-04 Shiseido Co., Ltd. Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
US20030158186A1 (en) * 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
CA2528718A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
AU2006245438A1 (en) * 2005-02-18 2006-11-16 Bellus Health (Innodia) Inc. Analogs of 4-hydroxyisoleucine and uses thereof
ES2364498T3 (es) 2005-08-30 2011-09-05 Takeda Pharmaceutical Company Limited Inhibidor de la secreción ácida.
NZ569293A (en) 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
UA105185C2 (uk) 2008-08-27 2014-04-25 Такеда Фармасьютікал Компані Лімітед Піроли
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
CN103998435A (zh) * 2011-10-04 2014-08-20 法国国家健康医疗研究院 新型细胞凋亡诱导化合物
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
EP3515889A1 (en) 2016-09-20 2019-07-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Trpv4 antagonists
AU2017330620A1 (en) 2016-09-20 2019-03-28 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954158A (en) * 1983-08-16 1990-09-04 University Of Georgia Research Foundation, Inc. 2,3-methanoproline
ZA877471B (en) * 1986-10-08 1988-04-05 Bristol-Myers Company 1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ATE198326T1 (de) * 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5795890A (en) * 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
AU725831C (en) * 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
AU741893B2 (en) * 1996-08-28 2001-12-13 Procter & Gamble Company, The Substituted cyclic amine metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) * 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US6261775B1 (en) * 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma

Also Published As

Publication number Publication date
NO990855L (no) 1999-04-23
AU741893B2 (en) 2001-12-13
US20020061877A1 (en) 2002-05-23
PE109098A1 (es) 1999-02-19
EP0927161A1 (en) 1999-07-07
EP0927161B1 (en) 2002-10-16
KR100323272B1 (ko) 2002-02-06
CA2263928A1 (en) 1998-03-05
JP3541043B2 (ja) 2004-07-07
US20020072517A1 (en) 2002-06-13
US20030191163A1 (en) 2003-10-09
CZ63199A3 (cs) 1999-08-11
CO4900036A1 (es) 2000-03-27
AU4074197A (en) 1998-03-19
TWI232218B (en) 2005-05-11
NZ334256A (en) 2000-11-24
ATE226193T1 (de) 2002-11-15
RU2221782C2 (ru) 2004-01-20
HUP0000478A2 (hu) 2000-09-28
PT927161E (pt) 2003-12-31
IL128666A0 (en) 2000-01-31
JP2000516955A (ja) 2000-12-19
HUP0000478A3 (en) 2000-10-30
NO990855D0 (no) 1999-02-23
BR9713465A (pt) 2000-03-28
IL128666A (en) 2005-09-25
US20050101567A1 (en) 2005-05-12
ZA977698B (en) 1998-02-23
KR20000035922A (ko) 2000-06-26
CN1232451A (zh) 1999-10-20
ES2201318T3 (es) 2004-03-16
US6858628B2 (en) 2005-02-22
DE69716449D1 (de) 2002-11-21
US20050154019A1 (en) 2005-07-14
US6569855B2 (en) 2003-05-27
HK1020962A1 (en) 2000-05-26
PL331802A1 (en) 1999-08-02
WO1998008815A1 (en) 1998-03-05
ID18143A (id) 1998-03-05
US6417219B1 (en) 2002-07-09
NO315371B1 (no) 2003-08-25
JP2004115531A (ja) 2004-04-15
TR199900431T2 (xx) 1999-04-21
MY116959A (en) 2004-04-30
DE69716449T2 (de) 2003-08-07
DK0927161T3 (da) 2003-02-17

Similar Documents

Publication Publication Date Title
SK25099A3 (en) Substituted cyclic amine metalloprotease inhibitors
KR100352316B1 (ko) 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
JP3347331B2 (ja) 複素環式メタロプロテアーゼ阻害剤
KR100400507B1 (ko) 치환 피롤리딘 히드록사메이트 메탈로프로테아제 억제제
KR20000035923A (ko) 헤테로고리성 메탈로프로테아제 저해제
KR100326611B1 (ko) 스피로시클릭 메탈로프로테아제 저해제
CZ63699A3 (cs) Sloučeniny na bázi amidů kyseliny fosfinové jako inhibitory metaloprotáz mezibuněčné hmoty, způsob jejich přípravy a jejich použití jako léčiv
KR20000035918A (ko) 1,3-디헤테로시클릭 메탈로프로테아제 저해제
SK24899A3 (en) Bidentate metalloprotease inhibitors
US6872742B2 (en) Substituted cyclic amine metalloprotease inhibitors
CZ20003734A3 (cs) Substituované pyrrolidinové hydroxamáty jako inhibitory metaloproteázy
MXPA99002064A (en) Heterocyclic metalloprotease inhibitors